Nitrosamine Drug Substance-Related Impurities (NDSRIs): A Practical Control Strategy Under FDA’s Revised Guidance
On 24 September 2026, FDA reversed a position it had defended for five years. CDER announced that the less-than-lifetime (LTL) approach described in ICH M7(R2) may now be applied to acceptable intake limits for nitrosamine impurities, an approach the agency had previously refused to accept. For sponsors sitting on a borderline NDSRI result in a short-duration product, the arithmetic of their entire control strategy just changed. team-mastery Why NDSRIs resist conventional impurity thinking Normal impurities (like NDMA) come from external pollution, but NDSRIs grow directly inside the medicine. Regular nitrosamine impurities usually get into drugs from the outside through dirty liquids, reused chemicals, or contaminated raw materials. NDSRIs form differently. They develop when tiny traces of chemicals called nitrites react directly with the core ingredients (APIs) of the medicine itself. Because they form from the medicine’s own structure, each NDSRI is unique to that specific drug. Because these impurities are unique to each specific drug, they cause three major issues: companies cannot buy ready-made chemical samples to test against, there is very little animal safety data to show how dangerous they are, and the chemical that triggers them (nitrite) is found everywhere in basic ingredients, factory water, and recycled liquids. This means the danger never really goes away, and the harmful impurities can keep forming throughout the medicine’s entire shelf life instead of just when the raw ingredients are being mixed. How the AI limit is actually assigned FDA’s August 2023 guidance, Recommended Acceptable Intake Limits for Nitrosamine Drug Substance-Related Impurities, supplies a methodology that uses structural features of the NDSRI to generate a predicted carcinogenic potency categorisation and a corresponding recommended AI limit, to be applied where no other FDA-recommended limit exists. The scheme assigns five potency categories, with Category 1 set at 26.5 ng/day, equal to the class-specific limit derived from NDEA, the most potent robustly tested nitrosamine and Category 5 at 1500 ng/day, the TTC per ICH M7(R2). fdapropharmagroup Two differences matter when a drug is being filed in multiple countries. The EMA’s Category 1 limit is 18 ng/day, compared with the FDA’s 26.5 ng/day. This means companies may need to justify their specifications to meet both agencies’ requirements. When more than one nitrosamine is present, the FDA recommends that the total amount stay within the acceptable intake limit of the most potent impurity found. The LTL adjustment: what it does and does not unlock Products with shorter treatment durations, as defined in approved labelling, may now justify higher AI limits, up to 80× the lifetime limit for treatments of one month or less, scaling down to no adjustment for durations exceeding ten years. The adjustment is not available for interim AI limits, including those in Table 3 of the nitrosamine guidance, and applicants with pending applications are expected to notify CDER if they intend to propose an LTL-adjusted limit and amend accordingly. FDA opens the door to LTL adjustment for nitrosamines +2 Treat LTL as a way to justify your control strategy, not as a reason to relax process controls. The permitted duration can change depending on the product label. If your control strategy only works at 80 times the acceptable intake limit, there is very little room for error. Building the control strategy from the chemistry backwards Remove the source of nitrite before trying to control the impurity. Check every stage of the process where nitrite could enter, including raw materials, recovered solvents, process water, and excipients in the finished product. Setting limits for nitrite in incoming materials can be less expensive than controlling it through the final drug product specification. Review the entire manufacturing process, not just the final step. Check for nitrous acid formed during quenching, leftover nitrite from diazotisation, and intermediates containing amines that may carry through to later steps. Under ICH M7(R2) principles, you need evidence to show how effectively these impurities are removed during the process. Make sure testing methods are sensitive enough. Testing often requires LC-MS/MS or GC-MS/MS methods that can detect impurities at sub-ppb levels. These methods need to be checked against a synthesised and fully characterised NDSRI reference standard. Getting this standard made can become one of the biggest delays in the programme. Use the 10% rule deliberately. A specification is not required where nitrosamine levels are consistently not more than 10 percent of the recommended AI limit, provided the root cause is well understood and manufacturing process controls are established and validated. That clause rewards mechanistic understanding and penalises sponsors who only have batch data. fda Design the formulation to reduce the risk. Antioxidants, pH control, and methods to remove or reduce nitrite can help limit NDSRI formation in the finished product. Regulators will look at stability data to see whether these measures work in practice. Where this lands Smart companies stop harmful impurities (NDSRIs) before they even form. Instead of waiting for final lab tests to catch problems, these manufacturers study the production process early on. They figure out exactly how these impurities might develop and design safety controls right from the start. LAXAI Life Sciences supports that work end to end. Our analytical R&D infrastructure, including UPLC-MS, LC-MS, GC-MS and Bruker 400 MHz NMR, underpins method development, impurity characterisation and reference standard qualification, while our process R&D team applies route scouting, process safety evaluation and QbD-based process development to engineer nitrosamine risk out of the synthesis itself. Across scale-up from 20 L to 250 L reactors and into cGMP API manufacture for US, European and Japanese markets, impurity control is designed into the process rather than tested into the batch.
India’s PLI Scheme for KSMs and APIs: How Domestic Backward Integration Is Reshaping Global API Supply
India’s pharmaceutical PLI schemes have beaten their investment targets and Chinese import dependence has gone up anyway. Against ₹46,744 crore of PLI investment recorded by June 2026, China’s share of India’s API, KSM and intermediate imports rose from 68.2% in FY21 to 73.7% in FY25, with the import value climbing from ₹18,646 crore to ₹27,032 crore. Any sourcing strategy built on the assumption that the scheme has already de-risked Indian supply is working from the wrong premise. retailintel What the scheme actually funds The government’s response to post-pandemic supply shock had two parts: a ₹6,940 crore production-linked incentive scheme for bulk drugs, and a separate ₹3,000 crore scheme for bulk drug parks. Incentives are paid on a percentage of incremental sales over a 2019–20 baseline, tapering across the scheme’s life, and cover more than 25 KSMs, drug intermediates and APIs including Penicillin G, 7-ACA and clavulanic acid. industry-reportnationalacademies Funding has arrived, and India is successfully bringing back the production of core medicine ingredients. By August 2025, companies invested ₹4,709 crore into the government’s bulk drugs incentive scheme (PLI), far exceeding the original target of ₹3,938.5 crore. Thanks to this money, local factories have already set up the capacity to make 26 different raw drug materials and ingredients. Crucially, India has restarted making fermentation-based antibiotics at home for the first time in 20 years, a critical category of medicine that the country had completely stopped manufacturing. Why the headline number hasn’t changed The real issue starts much earlier in the supply chain. Building a new medicine factory in India does not solve the risk if the core raw materials still come from just one supplier in China. Even though the final steps happen in India, the country remains dependent on China. India still needs to build a reliable domestic supply of these materials. This is why some new facilities set up under the “China Plus One” strategy continue to depend on Chinese suppliers for their KSMs. There are two other challenges. First, Chinese suppliers have historically lowered prices for key materials and bulk drugs when Indian manufacturers increase local production. This can make it harder for new Indian plants to compete and operate at full capacity.
From Non-GMP Tox Batch to GMP First-in-Human Batch: Bridging Impurity Profiles Without Repeating Tox Studies
A non-GMP toxicology batch can support an IND-enabling program successfully and still create a problem when the same drug candidate moves toward its first-in-human (FIH) GMP batch. The issue is not necessarily the molecule. It is the material. If the synthetic route changes between the tox batch and the GMP batch, the impurity profile can change with it. A new reagent, a different reaction condition, a change in purification, or a different process step can introduce impurities that were not present, or were not present at comparable levels, in the material used for toxicology. That creates a question for the CMC team: Does the toxicology package adequately cover the material that will actually enter the clinic? If the answer is unclear, additional analytical work, impurity qualification, or bridging studies may become necessary. The better place to address that risk is before the tox batch is manufactured. Why the Tox Batch Matters Beyond Toxicology The purpose of a tox batch is to supply material for nonclinical safety studies that support the move into human trials. ICH M3(R2) is explicit that nonclinical studies need to characterize potential adverse effects under conditions that actually reflect the planned clinical trial, which means the relationship between the tox material and the eventual clinical material isn’t a formality. It’s load-bearing. That makes the relationship between the tox material and the planned clinical material important. A tox batch produced using an early laboratory route may have a different impurity profile from a later GMP batch produced using a revised process. For example, a process-development team may change: A reagent or starting material Reaction conditions Solvent system Work-up procedure Purification method Reaction sequence Scale-dependent process parameters Each change can affect the impurities generated, carried forward, or removed during the process. The process may still produce the same API. The impurity profile may not be the same. Where Bridging Becomes Necessary Consider a program in which the non-GMP tox batch is manufactured using Route A. During process development, the team identifies a more scalable Route B for the GMP campaign. Route B offers better process control, improved yield, or a more practical manufacturing process. The molecule is the same. The manufacturing history is different. That difference needs to be understood analytically. The team needs to determine which impurities were present in the tox batch, which are present in the GMP material, whether new impurities have appeared, and whether any differences are significant for the safety package. This is where an impurity profile becomes more than a release-testing exercise. It becomes part of the bridge between the material used to establish nonclinical safety and the material intended for human exposure. The Cost of Addressing This Late It’s common to manufacture the tox batch first and sort out the GMP process later. That works fine when the process stays reasonably consistent. It stops working once a significant change happens after the tox material has already been used because now the team is reconstructing what changed, which impurities shifted, whether the new ones were present and qualified in the tox material, and whether more toxicological work is needed to close the gap. None of that means process changes should be avoided. Process development is supposed to evolve. The goal is making those changes with a clear picture of what they do to the material behind the nonclinical data, not discovering the gap after the fact. Bringing Process Development Into the Tox Strategy Early This is where process development can contribute before the tox batch is manufactured. Instead of treating the tox batch as a one-time material supply exercise, the process team can work backward from the intended clinical manufacturing route. That means asking What route is likely to support GMP manufacture? Which process steps could change during scale-up? Which reagents or intermediates could generate potentially relevant impurities? Which impurities are likely to carry forward? What analytical methods are needed to establish the impurity profile? How closely will the tox material represent the planned clinical material? The earlier these questions are addressed, the easier it becomes to design the tox batch with the eventual GMP transition in mind. LAXAI’s IND-enabling tox batch offering brings process development, scale-up, analytical support, and tox-batch manufacturing together. Its process-development approach is designed around developing scalable and reproducible processes before moving toward later-stage manufacturing. That integration matters because the tox batch should not sit at the end of one process and the GMP batch at the beginning of another. Building a Better Bridge to First-in-Human A sound IND-enabling strategy doesn’t assume the tox batch and the FIH batch will be identical in every detail. It builds enough process and analytical understanding to explain the relationship between them, route, impurity differences, supporting data, and documentation of what changed along the way. That doesn’t guarantee bridging work will never be required; regulatory expectations are case-specific and depend on the molecule and the extent of the change. But it meaningfully reduces the odds of discovering a comparability problem only after the tox studies are already done. For most programs, the most expensive impurity question is the one that surfaces after the route has already changed. The better time to build the bridge is before the tox batch is made. LAXAI Life Sciences brings process development, scale-up, analytical support, and tox-batch manufacturing together under one team, with process development approached around building scalable, reproducible routes from the outset so the tox batch and the GMP batch are built as one continuous process, not two separate ones meeting in the middle.
Custom Synthesis of Modified Nucleosides and Nucleotides: Securing Building Blocks for Antiviral and RNA Programs
A promising antiviral or RNA therapeutic program can slow down for a reason that has little to do with biology. The required building block is difficult to make consistently. Modified nucleosides and nucleotides can involve multiple stereochemical considerations, protecting-group strategies, difficult purification steps, and demanding analytical requirements. When the building block is needed at increasing quantities, a route that worked at laboratory scale may not be the route that works reliably at larger scale. That makes building-block supply part of the development strategy, not simply a procurement exercise. Why Modified Nucleosides Are Different Nucleosides and nucleotides are used across several areas of pharmaceutical development, including antiviral programs, RNA therapeutics, and gene-editing applications. Chemistry becomes more demanding when a program requires a modified structure. A modification can affect: Reaction selectivity Stereochemical control Protecting-group strategy Purification Stability Yield Analytical characterization The challenge is not simply synthesizing the target structure once. The challenge is developing a route that can repeatedly produce material at the required quality and quantity. LAXAI identifies modified nucleosides and nucleotides as a synthetic chemistry capability supporting antiviral drugs, RNA therapeutics, and gene-editing tools, with expertise in optimizing synthetic pathways to produce high-quality building blocks. Phosphoramidite Chemistry Adds Another Layer Phosphoramidite chemistry is the established basis for much therapeutic oligonucleotide synthesis. The broader manufacturing literature also points to purification and isolation as important downstream challenges affecting product quality, yield, scale, and cost. For a building-block supplier, that means synthesis cannot be planned in isolation from purification and analytical requirements. A route can convert cleanly and still create a purification problem that becomes difficult to manage at a larger scale. Material that clears one purity requirement may need additional work before it meets the specification required for the next stage of the program. The same applies to scale. A route that performs well at laboratory scale may require modification before it can deliver material consistently at larger quantities. From Custom Chemistry to Reliable Supply Custom synthesis is a different exercise from sourcing an off-the-shelf compound because the structure may be well defined while the route to it is not. A program might need a specific modified nucleoside, a nucleotide analogue, a phosphoramidite building block, a protected intermediate, or material at a defined stereochemistry and purity. The chemistry team then has to work backward from those requirements. Which route gives the right selectivity? Which intermediates can be isolated cleanly? Where are the main impurity risks? Can the route be scaled without creating a new set of problems at the next size up? These questions become part of the synthesis strategy rather than something addressed after the first successful batch. The Scale-Up Problem One of the easiest mistakes in custom synthesis is assuming that increasing the reactor size will simply reproduce a successful laboratory route. Scale changes the process. Mixing, heat transfer, reaction time, addition rates, crystallization behavior, and purification can all behave differently as the process moves beyond the laboratory. For complex nucleoside and nucleotide chemistry, those changes can affect both yield and impurity control. That is why route design needs to consider the intended scale early. A building block that takes several purification steps at laboratory scale may become commercially unattractive when those same operations are repeated at larger scale. A better route may require more work during development but provide a more practical path to increasing quantities. Purity Is Only One Part of the Requirement For a pharmaceutical building block, “high purity” is not the only target. Understanding what the impurities are, where they originate, and how reliably the process controls them is equally important. Stereochemical purity can also be critical for modified nucleosides, making analytical characterization part of the synthesis strategy rather than a check performed after the fact. This is particularly important when the building block will feed into a more complex downstream process, where an impurity or quality issue introduced early can become harder and more expensive to address later. Choosing a Custom Synthesis Partner For antiviral and RNA programs, the right question is not simply: “Can you make this molecule?” It is: “Can you make it reliably at the quantity, purity, and quality level the program will need next?” Before selecting a synthesis partner, it is worth asking: Has the partner worked with modified nucleosides or nucleotides with similar complexity? Can the route be developed beyond laboratory scale? How are stereochemical and impurity-related risks controlled? What purification and analytical capabilities are available in-house? Can the partner support increasing quantities as the program advances? Can the same chemistry team support route development and subsequent supply? These questions become particularly important when a building block is on the critical path for a larger RNA, oligonucleotide, or antiviral program. For a specialized building block on that critical path, the ability to reproduce the chemistry reliably at the next required scale matters more than simply demonstrating that the molecule can be synthesized once. LAXAI Life Sciences’ synthetic chemistry capabilities include modified nucleosides and nucleotides, along with scaffolds and building-block synthesis and analytical infrastructure. Its chemistry platform also includes a specialized kilo laboratory for compound production, supporting the broader need to consider scalability as part of synthetic route development.
PROTAC Synthesis Challenges: Linker Design, E3 Ligase Ligands, and Scalable Routes for Bifunctional Degraders
The average small molecule drug sits comfortably under 500 daltons. A typical PROTAC runs 700 to 1,200 well outside the chemical space Lipinski’s Rule of Five was built to describe. That single fact explains most of what makes these molecules hard to make: everything about their synthesis, purification, and scale-up runs against the assumptions conventional small molecule process chemistry was optimized for. Targeted protein degradation is one of the most active areas in small molecule drug discovery, and the biology is increasingly well understood. The chemistry to make these molecules reproducibly, at scale, and to GMP standard remains the harder problem and it’s the one that stalls more programs than target selection ever does. What Makes a PROTAC Different A PROTAC (Proteolysis Targeting Chimera) is a bifunctional molecule built from three connected parts: a warhead that binds the target protein, a linker, and a ligand that binds an E3 ubiquitin ligase. When all three come together, the PROTAC recruits the E3 ligase into proximity with the target, forming a ternary complex that tags the target for ubiquitination and degradation by the proteasome. That three-part architecture is the source of both PROTAC’s therapeutic promise and its synthesis burden. You are not optimizing one binding pocket you are synthesizing, purifying, and eventually scaling two fully formed drug-like fragments joined by a linker whose length and chemistry determine whether the whole assembly even works. Challenge One: Linker Design The linker is not passive scaffolding. Its length, flexibility, and composition directly control whether the ternary complex forms with the geometry needed for productive ubiquitination get it wrong and you get a PROTAC that binds both partners individually but never degrades the target. PEG-based linkers improve solubility but add flexibility that can hurt binding cooperativity. Alkyl linkers offer more rigidity and can improve potency but often worsen the already difficult solubility profile. Triazole linkages formed via click chemistry are popular precisely because they’re easy to install late in a synthesis, but the triazole itself becomes a permanent structural feature that affects the final molecule’s properties. Every linker choice trades one property against another, and that trade-off can only be resolved empirically, compound by compound. Challenge Two: E3 Ligase Ligand Synthesis Only a handful of E3 ligases have well-characterized, synthetically accessible ligands cereblon (CRBN), typically accessed through thalidomide-derived analogs like pomalidomide, and von Hippel-Lindau (VHL), whose ligands require multi-step, often stereoselective synthesis to install the hydroxyproline core correctly. Getting the stereochemistry wrong at this stage doesn’t just reduce yield it can produce an E3 ligand fragment that binds poorly or not at all, invisible until ternary complex testing fails downstream. The narrow number of validated E3 ligase ligands available today means most programs are working with the same handful of chemotypes, which concentrates synthetic difficulty rather than spreading it across easier alternatives. Challenge Three: Scalable, Convergent Routes At discovery scale, PROTACs are often made by whatever route gets material fastest frequently solid-phase synthesis or sequential solution-phase coupling. Neither translates cleanly to scale-up. The route that generally scales best is late-stage convergent coupling: synthesizing the warhead-linker fragment and the E3-ligand-linker fragment separately, then joining them in a single final coupling step often amide bond formation or copper-catalyzed azide-alkyne cycloaddition (CuAAC) click chemistry. This minimizes the number of steps performed on the full, high-molecular-weight molecule, where every operation becomes harder. Purification is where this molecular weight problem bites hardest. Des-linker impurities, homo-coupled byproducts, and unreacted fragment carryover are structurally similar to the target compound and difficult to resolve without heavy chromatography a purification strategy that becomes expensive and slow at multi-kilogram scale. Reducing chromatography dependency through crystallization-based purification, where the molecule’s structure allows it, is one of the clearest differentiators between a route that scales and one that doesn’t. The Regulatory Dimension Structural complexity doesn’t exempt a PROTAC from standard impurity control. ICH M7 mutagenicity assessment still applies to reagents, intermediates, and byproducts in the route, and ICH Q3A governs the broader impurity profile both made harder to execute when the molecule itself is large, flexible, and structurally similar to several of its own impurities. Analytical characterization under ICH Q6A and validated methods per ICH Q2(R2) require methods capable of resolving closely related, high-molecular-weight species, which is a materially harder analytical problem than a typical small molecule impurity panel. The Bottom Line PROTAC synthesis challenges are not a scaled-up version of ordinary small molecule chemistry they are a different problem shaped by molecular weight, fragment coupling, and a narrow set of E3 ligand chemotypes. Programs that treat route design and purification strategy as a discovery-stage afterthought pay for it heavily at scale-up. LAXAI Life Sciences specializes in designing and synthesizing bifunctional molecules for precise protein modulation, backed by a specialized kilo laboratory, cutting-edge analytical infrastructure, and a team of over 400 skilled scientists advancing PROTAC and targeted protein degradation programs from concept through scalable, GMP-ready routes within a fully integrated CRDMO framework.
FDA vs. EMA GMP Expectations for API Manufacturers: A Compliance Checklist for Outsourcing Partners
Ship the same API batch to the US and to the EU, and it can pass one market’s GMP review and stall in the other’s not because the chemistry changed, but because the paperwork behind it was built for only one regulator. Sponsors selecting a CRDMO for multi-market supply routinely discover this only after a filing is already in motion, when the fix is expensive, and the timeline is not forgiving. FDA and EMA agree on far more than they disagree on. But the gaps between them are specific, well documented, and entirely avoidable with the right outsourcing partner and the right questions asked upfront. The Shared Foundation Both agencies anchor API GMP expectations in ICH Q7, the harmonized guideline for good manufacturing practice of active pharmaceutical ingredients. Impurity control under ICH Q3A and mutagenic impurity assessment under ICH M7 apply identically on both sides of the Atlantic. This shared base is why a well-run CRDMO can genuinely serve both markets from the same facility; the divergence is in framework, documentation, and oversight mechanics, not in the underlying science. Where the Frameworks Diverge Regulatory instrument. FDA GMP requirements for APIs sit in 21 CFR Parts 210 and 211, applied to drug substances through ICH Q7. EMA’s requirements are codified in EudraLex Volume 4, Part II, the EU’s GMP guide specifically for active substances. Different legal instruments mean different inspection checklists, even when the underlying principle is the same. Master file system. In the US, a Drug Master File (DMF), typically Type II, holds confidential manufacturing information that FDA references during an ANDA or NDA review. The EU equivalent is the Active Substance Master File (ASMF), submitted to the EMA or national authorities in a different format, under different update procedures. A DMF is not automatically portable into an ASMF submission the dossiers must be built for each system. The Qualified Person requirement. The EU requires a named Qualified Person (QP) to certify that each batch has been manufactured and tested in accordance with GMP and the marketing authorization before release. The US has no direct equivalent. For a CRDMO supplying EU markets, QP certification readiness is not optional; it is a structural requirement with no US parallel to fall back on. Written Confirmation for imported active substances. Since 2013, active substances imported into the EU generally require a Written Confirmation from the exporting country’s regulatory authority, confirming the manufacturing site meets GMP standards equivalent to EU requirements unless the exporting country is on the EU’s equivalence list or the site has been directly inspected. This requirement has no US counterpart and has tripped up more than one otherwise well-qualified API supplier attempting to enter EU supply chains for the first time. Inspection mechanics. FDA inspections can be announced or unannounced and are risk-based, prioritizing sites by product risk and inspection history. EU inspections are coordinated through national competent authorities, often as part of a marketing authorization review. Since 2017, the FDA-EU Mutual Recognition Agreement has allowed both sides to rely on each other’s GMP inspections for human medicines in covered scopes, reducing duplicate inspections, but it does not eliminate the need for site readiness against both frameworks, since scope and product coverage under the MRA are not universal. Data integrity emphasis. Both regulators expect ALCOA+ principles, and both cite data integrity failures heavily in enforcement actions, but the specific guidance documents differ: FDA’s data integrity guidance versus MHRA’s GxP data integrity guidance, which EU inspectors reference closely even though the MHRA sits outside the EU post-Brexit. A Checklist for Evaluating an Outsourcing Partner Before committing to a CRDMO for multi-market API supply, confirm: The Bottom Line FDA and EMA GMP expectations converge on the science and diverge on the paperwork, the certifications, and the inspection mechanics that surround it. A CRDMO built to supply only one market will eventually surface that gap in the other, usually at the worst possible time. The right partner treats dual-market readiness as a standing capability, not a special request. LAXAI Life Sciences maintains cGMP manufacturing facilities equipped with advanced technologies and capabilities to support small molecule APIs supplied to the US, Europe, and Japan markets, with regulatory support spanning IND filing through NDA, ANDA, and DMF filing within a fully integrated CRDMO framework built for multi-market compliance.
In Vitro ADME vs. In Vivo DMPK Studies: What Early-Stage Biotech Needs to Know Before IND Filing
A compound can look flawless in a biochemical assay and still fail before it ever reaches a patient, cleared too fast by the liver, unable to cross a membrane, or metabolized into something toxic. That failure almost never shows up in the potency data. It shows up in ADME and DMPK, which is exactly why regulators require a defined package of both before an IND can move forward. For early-stage biotech teams building their first IND package, the in vitro versus in vivo question is not academic. It determines what gets studied, when, on how many animals, and at what cost, and getting the sequence wrong wastes both. Two Different Jobs, Not Two Versions of the Same Study In vitro ADME studies use isolated biological systems liver microsomes, hepatocytes, cell monolayers, plasma to characterize a compound’s absorption, distribution, metabolism, and excretion behavior in a controlled, high-throughput setting. In vivo DMPK studies put the compound into a live animal to measure what actually happens across an intact system: circulation, organ distribution, elimination, and the pharmacokinetic profile that predicts human dosing. These are not redundant checks. In vitro work is fast, cheap, and scalable; it can screen dozens of analogs before a single animal is dosed. In vivo work is slower and far more resource-intensive, but it is the only way to capture systemic behavior that isolated systems cannot replicate: whole-body clearance, first-pass metabolism, and the pharmacokinetic-pharmacodynamic relationship regulators actually need to see. What In Vitro ADME Covers Physicochemical and stability screening. Solubility in biorelevant media (FaSGF, FaSSIF, FeSSIF) and stability across plasma, blood, and pH conditions establish whether a compound will even survive long enough to be absorbed. Permeability assays. PAMPA, Caco-2, and MDCK-MDR1 assays predict oral absorption and blood-brain barrier penetration, critical data long before any dosing study is designed. Metabolism studies. Metabolic stability in liver microsomes and hepatocytes, metabolite identification, and CYP inhibition and induction profiling flag compounds likely to be cleared too quickly or to cause drug-drug interactions. Every one of these studies can disqualify a compound before it reaches an animal. That is precisely their value: they are a filter, not a formality. What In Vivo DMPK Adds Pharmacokinetics across species. Studies in mice, rats, dogs, and other models establish absorption, distribution, metabolism, and elimination in a living system that in vitro data can only estimate. Excretion and distribution studies. Metabolic cage studies and tissue distribution work show where a compound actually goes and how it clears, informing both efficacy and safety interpretation. Toxicology integration. In vivo DMPK doesn’t run in isolation from toxicology. Exposure data from PK studies directly informs dose selection and interpretation in IND-enabling tox studies. This is where a compound’s in vitro promise is tested against biological reality—and where a disconnect between the two datasets is often the first sign of a problem worth catching before GLP tox work begins. The Sequence That Avoids Wasted Spend The efficient path runs in vitro first, in vivo second, deliberately. Physicochemical and permeability screening eliminates unsuitable compounds at minimal cost. Metabolic stability and CYP data narrow the field further and flag likely species differences before they show up as confusing in vivo results. Only compounds that clear these filters advance to animal PK studies, and only the strongest candidates proceed to IND-enabling toxicology. Skipping or compressing this sequence is a common early-stage mistake. Running in vivo PK on a compound with an unresolved CYP inhibition flag, or without solubility data to explain a poor exposure result, both waste animals and produces PK data that is difficult to interpret without the in vitro context behind it. What Regulators Expect to See An IND-enabling DMPK package needs to demonstrate a coherent story: in vitro data that characterizes the compound’s ADME behavior, in vivo PK data across relevant species, and DMPK-tox integration that supports the proposed first-in-human dose. Gaps or inconsistencies between the in vitro and in vivo datasets are a common source of regulatory questions during IND review, which is why the two workstreams need to be planned together from the start, not bolted together after the fact. The Bottom Line In vitro ADME and in vivo DMPK are not competing approaches; they are sequential filters that, run in the right order, get a stronger candidate to IND with fewer animals and less wasted cost. The teams that struggle are usually the ones that treated one as a substitute for the other rather than a stage that feeds it. At LAXAI Life Sciences, our DMPK and Tox studies span in vitro ADME through in vivo pharmacokinetics, excretion, and distribution assessments across mice, rats, beagle dogs, rabbits, hamsters, and monkeys, supported by fast turnaround times and expert scientific interpretation that keeps your program moving from hit-to-lead through IND filing, within a fully integrated CRDMO framework.
Outsourcing Analytical Method Development: How to Set Up an Effective CRO Partnership Without Losing Data Integrity
Data integrity failures are among the most frequently cited problems in FDA warning letters to drug manufacturers, and a large share of them trace back to the analytical laboratory: deleted injections, reprocessed chromatograms, disabled audit trails, and results that cannot be reconstructed from the raw data. When that laboratory is a contract partner rather than your own, the risk does not disappear. It moves outside your walls, where it is harder to see and harder to control. Outsourcing analytical method development is one of the most common decisions a small molecule program makes. Done well, it buys instrumentation, expertise, and speed you would otherwise build in-house. Done carelessly, it hands the integrity of your regulatory data to a laboratory you cannot watch injection by injection. What You Are Actually Outsourcing Two things leave your building when you outsource method development, not one. The first is the method itself the HPLC, GC, or LC-MS procedure that will define your impurity profile, assay, and stability data. The second, and more consequential, is the data that method generates. That data will end up in your regulatory filings, and you are accountable for it regardless of who ran the instrument. This is the distinction that makes analytical outsourcing different from outsourcing synthesis. A kilogram of intermediate can be tested on receipt. A dataset cannot be re-verified after the fact if the underlying records were never sound. The Case for Outsourcing—and Its Limits The appeal is real. A capable CRO offers a full analytical suite NMR, UPLC-MS, GC-MS, prep HPLC—without the capital cost, plus specialists in method development and validation and the throughput to keep a program moving. For most sponsors, building all of that internally is neither fast nor economical. The limit is oversight. Every advantage of outsourcing someone else’s instruments, someone else’s analysts, someone else’s data systems is also a layer between you and the raw records. Closing that gap is the entire job of setting up the partnership correctly. Where Data Integrity Breaks Down The failure modes are consistent and well documented. Uncontrolled reprocessing. Analysts reintegrate peaks or reprocess runs until a result passes, without a documented, justified reason. Audit trails that no one reviews. Modern chromatography data systems record every action, but the record is only useful if someone reviews it. Unreviewed audit trails are where manipulation hides. Orphan and trial injections. “Test” injections run before the official sequence, then quietly discarded, are a classic pattern flagged in regulatory inspections. Weak computerized system controls. Shared logins, no unique user attribution, and systems that let data be deleted or overwritten violate both 21 CFR Part 11 and basic ALCOA+ expectations. What Good Looks Like: ALCOA+ The standard for sound data is captured in the ALCOA+ principles: data must be Attributable, Legible, Contemporaneous, Original, and Accurate, plus Complete, Consistent, Enduring, and Available. FDA’s data integrity guidance and the MHRA’s GxP data integrity guidance both build on this framework, and inspectors apply it directly to contract laboratories. A CRO partnership that cannot demonstrate ALCOA+ across its analytical records is a liability no matter how good the science looks. Setting Up the Partnership Right A quality agreement that names data integrity explicitly. Define who owns the raw data, where it lives, how it is backed up, and your right to access it, including audit trails at any time. Raw data access, not just reports. Insist on access to the underlying electronic records, not only the summary tables. A polished report built on records you cannot inspect is not evidence. Defined audit trail review. Specify that audit trail review is part of the CRO’s data review, and confirm it during qualification audits rather than assuming it happens. Computerized system validation and Part 11. Confirm the CRO’s chromatography data systems are validated, enforce unique user access, and prevent deletion or silent overwriting of data. A method transfer plan from the start. The method will eventually move to your site or to a manufacturing partner. Building transfer protocols and acceptance criteria into the engagement early prevents a scramble later. Anchor It in the Right Guidance Method development and validation should follow ICH Q2(R2) for validation and ICH Q14, which introduces a structured, enhanced approach to analytical procedure development. Data integrity expectations should be governed explicitly by FDA and MHRA guidance and enforced through the quality agreement. Naming these standards in the contract turns “trust us” into a set of verifiable obligations. The Bottom Line An effective analytical CRO partnership is built on visibility. You are not outsourcing accountability for your data, only the work that produces it, so the partnership must be structured to keep the raw records, the audit trails, and the transfer path fully within your reach. At LAXAI Life Sciences, our analytical experts work alongside our chemists to develop and validate methods for purification, isolation, and characterization, delivering method development, validation, and transfer that adhere to global regulatory standards within a fully integrated CRDMO framework built for data you can stand behind.
KSM and RSM Sourcing Strategies for Phase III and Commercial API Supply: Reducing Single-Source Risk
The moment a regulatory starting material is written into a Phase III filing, its supplier becomes one of the hardest things in the entire process to replace. Change it later, and you may trigger a regulatory variation, a comparability exercise, and months of requalification for a molecule that is already in patients or on the market. This is precisely the stage at which many programs discover they have built their commercial supply on a single supplier, in a single country, with no qualified backup. Single-source risk is not a procurement footnote. For a Phase III or commercial API, it is one of the most consequential decisions a program makes, and the window to fix it cheaply closes fast. KSM vs. RSM: Why the Distinction Drives the Risk A Key Starting Material (KSM) is a material essential to the synthesis of an API. A Regulatory Starting Material (RSM) is the point in the synthetic route that regulators designate as the beginning of GMP manufacturing—everything downstream is scrutinized in the filing; everything upstream is not. Where the RSM is set therefore defines how much of your supply chain regulators actually see. ICH Q11 governs this designation, and the principle it establishes is consequential: an RSM should be a well-characterized, isolated, and stable material, with the steps that form the API’s core structure kept inside the regulated portion of the route. Set the RSM too late, and you shorten your regulated route but hand more control and more risk to an upstream supplier operating outside GMP scrutiny. Why Single-Source Risk Concentrates at Phase III In early development, sourcing is opportunistic. You buy what gets the program moving. That flexibility disappears as the process is locked for registration. Filings freeze the supply chain. Once a supplier and route are in the regulatory submission, changing them becomes a regulated event with its own timeline and cost. Geographic concentration. A large share of the world’s KSMs and advanced intermediates originates from a small number of suppliers concentrated in a few regions. A single plant shutdown, export restriction, or quality action can idle a commercial product. Quality events cascade. The nitrosamine crisis showed how a single upstream supplier issue can ripple across dozens of finished products at once. Supplier quality is now a supply-continuity issue, not just a compliance one. The Strategies That Reduce It Dual sourcing. The most direct answer is qualifying a second supplier for critical KSMs and RSMs. It costs money and requalification effort upfront, but it removes the single point of failure that can halt commercial supply entirely. Backward integration. Bringing KSM or intermediate manufacture in-house—or into a trusted CRDMO partner—reduces dependence on external suppliers and tightens control over quality and timing. It trades supplier risk for capacity commitment. RSM designation strategy. Choosing where to set the RSM is itself a risk lever. Positioning it to keep more of the route inside the regulated, controllable portion reduces exposure to opaque upstream supply, though it increases the regulated manufacturing burden. Geographic diversification. Even with dual sourcing, two suppliers in the same region share the same disruption risks. Spreading sources across regions guards against localized shocks, export controls, regional shutdowns, and logistics failures. Safety stock and forecasting. Strategic inventory of critical materials buys time to respond to a disruption. It ties up capital, so it is a buffer, not a substitute for a qualified second source. The Regulatory Trade-Offs Are Real None of these strategies is free of regulatory friction. Adding a second supplier means generating comparable data and, in many cases, filing a variation or supplement. Repositioning an RSM changes the scope of what must be validated and reported. Backward integration adds facilities that must be qualified and inspected. The practical consequence is that these decisions belong early in development, not after a filing. A second source designed into the original submission is far cheaper than one bolted on after approval, when every change is a regulated variation against a live product. The Bottom Line Supply security for a commercial API is built, not bought at the last minute. It comes from deliberate choices about where to set the RSM, whether to dual-source, how much to integrate, and how widely to diversify, made while the process still has the flexibility to absorb them. LAXAI Life Sciences provides high-quality KSMs and RSMs backed by global sourcing capabilities and stringent quality control, with a secure supply of regulatory starting materials critical to API synthesis. With a proven history of supplying small-molecule APIs to the US, Europe, and Japan markets, we help programs build resilient, compliant supply chains from starting materials through commercial API within a fully integrated CRDMO framework.
Green Chemistry in Pharmaceutical Manufacturing: How CRDMOs Are Reducing Solvent Waste and PMI
Making one kilogram of active pharmaceutical ingredient can generate 25 to over 100 kilograms of waste. Most of that waste is not the reaction itself; it is solvent. Solvents typically account for 80 to 90 percent of the total mass consumed in a small molecule process, which means the single largest environmental and cost lever in API manufacturing is not the chemistry on paper, but everything poured in around it. This is why green chemistry has moved from a corporate talking point to a core metric on the manufacturing floor. And it is why CRDMOs, who run these processes at scale on behalf of many clients, sit at the center of the effort to reduce it. What PMI Actually Measures Process Mass Intensity (PMI) is the total mass of everything used to make a product reagents, solvents, water, processing aids divided by the mass of product obtained. A PMI of 50 means fifty kilograms went in for every kilogram of API that came out. PMI became the pharmaceutical industry’s preferred sustainability metric because it is simple, hard to game, and directly tied to cost. Every kilogram counted in PMI had to be purchased, handled, and eventually disposed of or recovered. The closely related E-factor measures waste per unit of product; both point at the same culprit, and both put solvents at the top of the list. The ACS Green Chemistry Institute Pharmaceutical Roundtable, formed by major drug companies, has driven much of this work, publishing solvent selection guides, PMI benchmarks, and reaction tools that are now industry reference points. Where the Waste Comes From Three sources dominate solvent consumption in a typical route. Reaction solvents. The medium the chemistry runs in, often used in large excess to keep reagents in solution and control temperature. Workup and extraction. Washing, quenching, and phase separations consume large solvent volumes that never touch the reaction itself. Isolation and purification. Crystallizations, chromatography, and recrystallizations: each isolation step adds solvent, and a multi-step route stacks these up quickly. A route with six isolated intermediates carries six full cycles of reaction solvent, workup, and purification. Removing even one or two isolations can cut total solvent demand dramatically. The Levers CRDMOs Pull Solvent selection and substitution. The first move is replacing hazardous or hard-to-recover solvents with greener alternatives, swapping dichloromethane or DMF for 2-MeTHF, cyclopentyl methyl ether, or, where possible, water. Solvent selection guides rank options by safety, environmental impact, and recoverability, making substitution a systematic exercise rather than a guess. Solvent recovery and recycling. At scale, distilling and reusing solvent is often the biggest single PMI reduction available. A recovered solvent stream can drop the effective PMI of a step by a large margin without changing the chemistry at all. This is where a well-equipped manufacturing site earns its keep. Telescoping to eliminate isolations. Carrying an intermediate forward in solution without isolating and drying it removes an entire cycle of workup and purification solvent. Telescoped sequences cut PMI, shorten cycle time, and reduce handling of unstable intermediates all at once. Catalysis over stoichiometric reagents. Replacing stoichiometric oxidants, reductants, or coupling reagents with catalytic methods reduces both reagent mass and the aqueous and organic waste generated in their workup. Flow chemistry and process intensification. Continuous processing often runs at higher concentration and with tighter control than batch, reducing solvent volumes and enabling reactions that would otherwise require large dilution for safety. Route redesign. The most powerful lever is also the earliest: designing a shorter, more convergent synthetic route from the start. Fewer steps mean fewer solvents, fewer isolations, and a structurally lower PMI that no amount of downstream optimization can match. Why This Matters Commercially Green chemistry is often framed as an environmental obligation, but the business case is just as direct. Lower solvent consumption means lower raw material costs, lower waste-disposal costs, and often faster, more robust processes. Regulators increasingly expect sustainability considerations in process development, and pharma clients now evaluate manufacturing partners on ESG performance alongside quality and cost. For a CRDMO, PMI reduction is not a side project. It is where cost efficiency, safety, regulatory readiness, and sustainability converge in a single set of decisions made during route and process development. The Bottom Line The greenest kilogram of solvent is the one never used. Meaningful PMI reduction comes from decisions made early route choice, solvent selection, and how many isolations a process truly needs—reinforced later by recovery and recycling at scale. At LAXAI Life Sciences, green chemistry principles are built into our process development from route scouting onward, alongside a focus on minimizing resource utilization and delivering sustainable solutions. The result is processes that are cleaner, more cost-effective, and easier to scale advancing your program while reducing its footprint, within a fully integrated CRDMO framework.
